[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,103,529
  • Shares Outstanding, K 251,355
  • Annual Sales, $ 2,320 M
  • Annual Income, $ 782,570 K
  • EBIT $ 937 M
  • EBITDA $ 966 M
  • 60-Month Beta 0.42
  • Price/Sales 6.18
  • Price/Cash Flow 18.86
  • Price/Book 7.41

Options Overview Details

View History
  • Implied Volatility 40.40% (+0.14%)
  • Historical Volatility 31.94%
  • IV Percentile 59%
  • IV Rank 30.88%
  • IV High 71.05% on 10/17/25
  • IV Low 26.71% on 08/28/25
  • Expected Move (DTE 7) 2.59 (4.54%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,067
  • Volume Avg (30-Day) 1,277
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 39,603
  • Open Int (30-Day) 29,101
  • Expected Range 54.51 to 59.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.75
  • Number of Estimates 4
  • High Estimate $0.79
  • Low Estimate $0.68
  • Prior Year $0.65
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.80 +12.40%
on 06/22/26
57.57 -0.82%
on 07/07/26
+4.11 (+7.76%)
since 06/09/26
3-Month
43.50 +31.26%
on 05/04/26
57.57 -0.82%
on 07/07/26
+11.69 (+25.74%)
since 04/09/26
52-Week
33.76 +69.16%
on 10/20/25
57.57 -0.82%
on 07/07/26
+13.03 (+29.57%)
since 07/09/25

Most Recent Stories

More News
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver...

EXEL : 57.10 (+1.76%)
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –

EXEL : 57.10 (+1.76%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

- Presentations to be webcast on www.exelixis.com -

EXEL : 57.10 (+1.76%)
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...

EXEL : 57.10 (+1.76%)
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –

EXEL : 57.10 (+1.76%)
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial –

EXEL : 57.10 (+1.76%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

- Presentations to be webcast on www.exelixis.com -

EXEL : 57.10 (+1.76%)
Exelixis: Q1 Earnings Snapshot

Exelixis: Q1 Earnings Snapshot

EXEL : 57.10 (+1.76%)
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted...

EXEL : 57.10 (+1.76%)
Exelixis Reports Tomorrow With Competitive Questions It Has Not Yet Answered

Barchart Research What to Expect from EXEL Earnings EXEL Generated May 4, 2026 Current Price $44.17 EPS Estimate $$0.67 Consensus Rating Moderate Buy Average Move 9.60% Exelixis Reports Tomorrow With Competitive...

EXEL : 57.10 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 59.07
2nd Resistance Point 58.25
1st Resistance Point 57.67
Last Price 57.10
1st Support Level 56.27
2nd Support Level 55.45
3rd Support Level 54.87

See More

52-Week High 57.57
Last Price 57.10
Fibonacci 61.8% 48.47
Fibonacci 50% 45.66
Fibonacci 38.2% 42.85
52-Week Low 33.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.